A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer

Pre-clinical and retrospective clinical data indicates hENT1 may be a predictive and prognostic biomarker for gemcitabine (Gem) efficacy. To ultimately prove its use as a biomarker, a prospective randomized study with hENT1 stratification is required. This study would provide the highest level of confidence, and would, if positive, vault Gem into the select few anticancer agents for which a truly sensitive population can be rationally treated. By this "molecular triage", the risk/benefit ratio of Gem therapy for pancreas cancer (PC) could be meaningfully improved while also providing rationale for the use of a different treatment regimen should tumours have low hENT1. The comparator arm of FOLFOX was chosen because of the recent data showing impressive patient outcomes with the use of oxaliplatin-based treatments.

This is a randomized, open-label, multicentre, phase III trial in which eligible patients with metastatic pancreatic adenocarcinoma will be randomized between Gem and FOLFOX with predefined upfront testing for hENT1. To be eligible, patients will have to have adequate tissue available for hENT1 testing which the Cross Cancer Institute (CCI) will ensure prior to treatment randomization. Patients will have their tumour sample tested for the expression of hENT1. A blinded pathologist with expertise knowledge and experience with hENT1 staining at the lead centre (CCI) will be responsible for pathologic hENT1 classification via IHC. hENT1 IHC will be determined and scored as previously outlined.(1) Once hENT1 status has been confirmed, patients will then be randomized 1:1 between Gem and FOLFOX. Patients will be treated on study until disease progression, overwhelming toxicity, or patient withdrawal of consent. Dose adjustments for one or more of the study drugs will be based on toxicities encountered by individual patients. Specific dose-adjustment and treatment guidelines for hematologic and non-hematologic toxicities including neutropenia, diarrhea, renal toxicity, and neurotoxicity will be outlined in the protocol. Prior to enrolment, screening procedures will document compliance with inclusion and exclusion criteria. The primary endpoint will be determination of the difference in PFS in the two study arms, defined from the study start date until either an increase in the sum of the products of the diameters of measurable lesions by ≥ 20% bases on revised RECIST guidelines version 1.1 (2), the appearance of any new lesion, or a deterioration in clinical status that is consistent with disease progression. Secondary endpoints will be determination of the differences in overall response rate (ORR), disease control rate (DCR), and overall survival (OS). Administered dose intensity of Gem and FOLFOX will be reported. Health-related quality of life (HRQL) will be assessed for the duration of active treatment on study.

Patient Population: The target population is patients with measurable metastatic adenocarcinoma of the pancreas who have not been previously treated with systemic therapy for their metastatic disease and who have tumour samples amenable to hENT1 testing. Fine needle aspiration biopsies will not be permitted. Patients who have received prior chemotherapy delivered as part of initial curative therapy (i.e. neoadjuvant, adjuvant, and/or concurrently delivered with radiation and/or surgery) are permitted as long as that treatment was completed at least 6 months prior to study start date. Patients may have received prior radiotherapy or surgery ≥ 4 weeks before study entry and must have recovered from the toxic effects from any prior therapy. Patients with locally advanced adenocarcinoma of the pancreas will be excluded. Full inclusion and exclusion criteria are detailed in the protocol.

Study Objectives:

Primary Objective: To determine the difference PFS between Gem and FOLFOX treated patients in hENT1 high and hENT1 low pancreatic adenocarcinoma.

Secondary Objectives: 1) To determine the difference in ORR between the two treatment arms; 2) To determine the rate of disease control, defined as the sum of complete response rate, partial response rate, and stable disease between the two treatment arms; 3) To determine the difference in OS between the two treatment arms; 4) To determine the differences in HRQL of patients on the two treatment arms.

Exploratory Objectives: 1) To investigate the role of hCNT3 and its interaction with hENT1-related patient outcomes. 2) To evaluate excision repair cross complementing 1 (ERCC1) and microsatellite instability (MSI) in tumour samples, both of which are increasingly being linked to efficacy in oxaliplatin-based therapy but for which information in PC is lacking.

Duration of Treatment: Treatment will continue until objective or symptomatic disease progression, overwhelming toxicity, or patient withdrawal of consent. A patient may continue to receive all or any combination of study drugs for as long as the investigator feels is appropriate, but will be discontinued from study in case of:

1. Clinical and/or radiological documented disease progression (as determined by revised RECIST 1.1 criteria).(2) All drugs will be discontinued and the patient removed from study; 2) Occurrence of unacceptable toxicity (this may be due to one or more drugs resulting in one or more study drug discontinuation); if all three drugs are discontinued the patient will be removed from study; 3) Failure to recover from hematologic and/or non-hematologic toxicity to re-treatment level despite dosing interruption of up to 28 days (this may be due to one or more study drugs resulting in one or more study drug discontinuation); if all drugs in regimen are discontinued the patient will be removed from study; 4) Patient's request (withdrawal of consent) or Investigator's recommendation (this may be one or more study drugs); if all three study drugs are discontinued patient will be removed from study; 5) Patient death (complete Serious Adverse Event Report for deaths occurring within 30 days after last study drug dose OR for deaths occurring after 30 days, only if considered related to study drug).

Efficacy Endpoints: Response assessments will be performed every 8 weeks, regardless of treatment cycle. History, physical exam, laboratory work, imaging, ECOG performance status (PS), will be required at each response assessment. PS will be measured using the ECOG performance status scale. Tumor marker (CA19-9) may be followed at the discretion of the investigator but should not be used in determination of disease response and are not a requirement of the study. Tumor response will be evaluated according to the revised RECIST criteria 1.1.(2) Symptomatic progression will be defined as new or worsening disease symptoms deemed by the treating oncologist to incompatible with continuation of study medication or the requirement for palliative radiation therapy or a fall in ECOG performance status to ≥ 3 deemed to be due to disease and not study treatment. Should symptomatic progression occur, imaging to confirm progression is advised but if not possible due to performance status, the study stop date will be recorded as the date of progression.

Safety: The NCI CTCAE (version 4.0) will be used to evaluate the clinical safety of the treatment in this study. Subjects will be assessed for adverse events at each clinical visit and as necessary throughout the study. Safety will be assessed via vital signs, physical exams, laboratory tests (including hematologic, serum chemistry, and liver function testing), and adverse event determination. Pregnant and nursing females will be excluded from participation in the trial.